English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

The biology of Peroxisome proliferator-activated receptor (PPAR) alpha (α) and gamma (γ) has been intensely scrutinized for the last 20 years and the clinical use of both PPAR-α (fibrates) and PPAR-γ (thiazolididiones) agonists has led to the understanding of their key role in the treatment of hypertriglyceridemia and type 2 diabetes mellitus [1, 2]. In contrast, the understanding of PPAR delta (δ) biology still lags behind. The identification of small molecule agonists for PPAR-δ has shed some light on the function of this ubiquitously expressed receptor in preclinical models and early clinical studies [3]. They have revealed the multiple benefits of PPAR-δ activation on lipid disorders, diabetes, and inflammation [3, 4]. However, synthetic PPAR-δ agonists have yet to be marketed for clinical use in humans, partly due to the burden associated with their clinical development [3].

ppar research

Peroxisome Proliferator-Activated Receptor<mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"><mml:mi>δ</mml:mi></mml:math>: A Target with a Broad Therapeutic Potential for Drug Discovery

Peroxisome Proliferator-Activated Receptorδ: A Target with a Broad Therapeutic Potential for Drug Discovery